Orforglipron Cuts Systolic BP 6.1 mm Hg in ATTAIN Analyses, GLP-1 Peptide Data Show
Orforglipron, the once-daily oral GLP-1 receptor agonist approved by the FDA in April 2026 for chronic weight management, lowered office systolic blood pressure (SBP) versus placebo over 72 weeks in adults with obesity, according to post hoc analyses of the ATTAIN-1 and ATTAIN-2 trials presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. The analyses, reported by Pharmacy Times, also suggest that part of the blood-pressure effect may occur independently of weight loss, a finding that carries direct implications for how peptide therapy clinics and telehealth prescribers monitor patients.
The result matters to the peptide therapy and research peptide industry because it widens the clinical conversation around GLP-1 peptide drugs beyond scale weight. Clinics that already manage GLP-1 patients for obesity and type 2 diabetes may need to think about blood-pressure tracking, antihypertensive regimens and patient counseling as part of routine peptide therapy follow-up, even though the new data are exploratory and do not establish a cardiovascular indication.
What happened at AHA 2026
The analyses drew on two randomized, placebo-controlled trials. ATTAIN-1 (NCT05869903) randomly assigned 3127 adults with obesity and without diabetes to orforglipron 6 mg, 12 mg or 36 mg, or placebo, alongside a healthy diet and physical activity. ATTAIN-2 (NCT05872620) randomly assigned 1613 adults with type 2 diabetes, a body mass index of 27 kg/m2 or higher and glycated hemoglobin of 7% to 10% to the same doses or placebo. Both trials supported the FDA approval of orforglipron, marketed as Foundayo by Eli Lilly and Company, for adults with obesity or overweight with weight-related medical problems as an adjunct to a reduced-calorie diet and increased physical activity.
In the new post hoc work, investigators assessed changes in office SBP and diastolic blood pressure (DBP) over time and grouped participants by baseline blood-pressure category using ACC/AHA criteria: normal (below 120 and below 80 mm Hg), elevated (120-129 and below 80 mm Hg), stage 1 hypertension (130-139 or 80-89 mm Hg) and stage 2 hypertension (140 or above, or 90 mm Hg or above). A mixed model for repeated measures compared overall blood-pressure changes between groups.
Key numbers: systolic and diastolic changes at 72 weeks
At 72 weeks, pooled orforglipron reduced SBP by 6.1 mm Hg versus 0.8 mm Hg with placebo in ATTAIN-1, and by 4.9 mm Hg versus 1.5 mm Hg in ATTAIN-2 (P < .001 for both). Diastolic results were less consistent. DBP declined significantly more with orforglipron in ATTAIN-1 (-2.5 versus -0.9 mm Hg; P < .001) but not in ATTAIN-2 (-1.3 versus -1.4 mm Hg; P = .87).
| Endpoint (72 weeks) | ATTAIN-1 (obesity, no diabetes) | ATTAIN-2 (type 2 diabetes) |
|---|---|---|
| Participants randomized | 3127 | 1613 |
| Systolic BP, orforglipron vs placebo | -6.1 vs -0.8 mm Hg (P < .001) | -4.9 vs -1.5 mm Hg (P < .001) |
| Diastolic BP, orforglipron vs placebo | -2.5 vs -0.9 mm Hg (P < .001) | -1.3 vs -1.4 mm Hg (P = .87) |
| SBP, stage 1 hypertension | -7.6 vs -1.7 mm Hg (P < .001) | -5.6 vs -2.3 mm Hg (P < .001) |
| SBP, stage 2 hypertension | -15.9 vs -11.1 mm Hg (P < .001) | -15.8 vs -8.2 mm Hg (P < .001) |
| Share of SBP change attributed to weight loss | About 58% | 80.8% |
Across baseline categories, SBP reductions were greater than placebo in both stage 1 and stage 2 hypertension in both trials (P < .001 for all). The largest absolute reductions appeared in stage 2 hypertension: 15.9 versus 11.1 mm Hg in ATTAIN-1 and 15.8 versus 8.2 mm Hg in ATTAIN-2. Investigators noted that placebo groups in the stage 2 subgroups also declined substantially, which makes the placebo comparison central to interpreting these figures.
Diastolic changes by category were reported without P values. In ATTAIN-1, DBP fell 3.6 versus 2.4 mm Hg in stage 1 and 8.4 versus 6.7 mm Hg in stage 2; in ATTAIN-2, the corresponding figures were 2.4 versus 2.1 mm Hg and 6.5 versus 5.4 mm Hg. The abstract did not report statistical significance for these comparisons.
Why the weight-loss mediation finding matters for peptide therapy
A mediation analysis attributed about 58% of the SBP change in ATTAIN-1 and 80.8% in ATTAIN-2 to weight reduction. The investigators concluded that orforglipron improved SBP across baseline blood-pressure categories and that the blood-pressure-lowering effect appeared at least in part independent of weight loss.
That interpretation is an investigator conclusion drawn from a statistical decomposition, not an independently verified mechanism. Industry observers note that mediation analyses rest on assumptions about which variables are measured and how they are modeled, and the abstract did not detail those assumptions. For peptide therapy clinics, the practical takeaway is narrower: GLP-1 peptide drugs such as orforglipron may influence blood pressure through more than one pathway, and the size of the effect varies by baseline blood-pressure status.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. Clinics evaluating GLP-1 protocols can use the ATTAIN subgroup data as a counseling reference while keeping in mind that the analyses were post hoc and assessed office readings only.
Research and market context for GLP-1 peptide drugs
Orforglipron belongs to the GLP-1 receptor agonist class, the same broad family as semaglutide, which acts on the GLP-1 receptor, and tirzepatide, which activates both GIP and GLP-1 receptors. Their approved products, indications, dosing, contraindications and labeling differ, and medical decisions should be based on the relevant product labeling and professional evaluation. Unlike injectable GLP-1 products, orforglipron is taken once daily without food or water restrictions, a difference that may matter for adherence and for how clinics structure follow-up.
The primary ATTAIN-1 publication previously reported that SBP significantly improved with orforglipron, along with waist circumference, triglycerides and non-high-density lipoprotein cholesterol. The new analyses extend that picture by breaking results down by hypertension stage, but they do not add a cardiovascular outcomes endpoint, and no data were reported for participants with normal or elevated baseline blood pressure.
From a supply-chain perspective, oral GLP-1 peptides shift demand away from injection pens, cartridges and vial-based fill-finish capacity toward oral solid-dose manufacturing and API supply. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates. Buyers tracking these shifts typically compare batch documentation, impurity profiles and analytical methods rather than relying on a single purity figure, since chromatographic purity and assay content measure different things.
What clinics and prescribers should watch
The analyses were post hoc, assessed office blood-pressure readings only and did not report changes to antihypertensive medications. That last gap is operationally important: if patients starting a GLP-1 peptide drug are also on blood-pressure medication, prescribers may need to monitor readings and review regimens, but the presented data do not quantify how often medication adjustments occurred or what clinical events followed.
- Baseline matters: the largest absolute SBP reductions appeared in stage 2 hypertension, where placebo responses were also large.
- Diastolic signals are mixed: significant in ATTAIN-1, not significant in ATTAIN-2.
- Unreported subgroups: no results were presented for normal or elevated baseline blood pressure.
- Medication data absent: antihypertensive changes were not reported.
For research peptide suppliers and compounding-adjacent businesses, the distinction between an FDA-approved medicine, a compounded drug and a research chemical remains essential. Approved medicines have undergone the applicable regulatory review for their approved uses; compounded drugs are prepared under specific legal conditions and are not FDA-approved as compounded products; research chemicals are intended for scientific use and should not be assumed suitable for human treatment. Research-use labeling does not establish sterility, safety or authorization for human administration, and a certificate of analysis does not independently establish clinical safety or efficacy.
What comes next
Full presentations and any peer-reviewed publication of the ATTAIN blood-pressure analyses will be needed to judge whether the subgroup and mediation findings hold up, and whether future work reports ambulatory readings, antihypertensive medication changes and results in participants with normal or elevated baseline blood pressure. Until then, the data support a cautious reading: orforglipron lowered office SBP versus placebo in adults with obesity, with or without type 2 diabetes, and the effect appears at least partly independent of weight loss according to the investigators.
Peptide industry professionals tracking GLP-1 research can follow conference abstracts and labeling updates through resources such as peptidescm, which aggregates supply-chain and industry news for the peptide sector. Additional first-hand reporting and supplier intelligence are available via PeptideDDP for teams that need to verify sourcing and documentation claims.